Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade Glioma. HCPs - Find trial and enrollment info here:

1,217,031 Aufrufe • vor 1 Jahr •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across partnerships, clinical programs, and financial goals. 🚀 Highlights include: ▪️Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery ▪️ REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 ▪️ REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα ▪️Reduced 2026 cash operating expense guidance to <$375 million (from <$390 million) "Recursion has reached a pivotal point where our AI-native engine is translating unique data into potential first-in-class therapeutic opportunities," said Recursion CEO Najat Khan, PhD. "The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled." 💠 Recursion will host an Earnings Call today, August 5, 2026, at 8:00 am ET / 6:00 am MT / 1:00 pm BST. Join on: ▪️X: ▪️YouTube: ▪️LinkedIn: Analysts, investors, and the public have the opportunity to ask questions of the Company by submitting questions here:

Recursion

202,684 Aufrufe • vor 2 Monaten